ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.949,05
1,06%
Brent Oil
84,85
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Elevai Labs Inc (ELAB)

  7. Elevai Labs Inc (ELAB) Notícias

ELAB

Elevai Labs (ELAB)

Elevai Labs Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELAB
DataHoraFonteTítuloCódigoCompanhia
28/06/202410:00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product LineNASDAQ:ELABElevai Labs Inc
26/06/202410:00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024NASDAQ:ELABElevai Labs Inc
14/06/202410:00GlobeNewswire Inc.Elevai Labs Forms New Scientific Advisory Board for its Weight Loss ProgramsNASDAQ:ELABElevai Labs Inc
31/05/202421:10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELABElevai Labs Inc
29/05/202410:00GlobeNewswire Inc.Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in StockholmNASDAQ:ELABElevai Labs Inc
24/05/202417:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
22/05/202417:15GlobeNewswire Inc.Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 ConferenceNASDAQ:ELABElevai Labs Inc
15/05/202417:30GlobeNewswire Inc.Elevai Labs Inc. Reports First Quarter 2024 Financial ResultsNASDAQ:ELABElevai Labs Inc
15/05/202417:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELABElevai Labs Inc
02/05/202409:30GlobeNewswire Inc.Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityNASDAQ:ELABElevai Labs Inc
01/05/202417:00GlobeNewswire Inc.Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareNASDAQ:ELABElevai Labs Inc
01/05/202410:00GlobeNewswire Inc.Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity TreatmentsNASDAQ:ELABElevai Labs Inc
29/04/202410:45GlobeNewswire Inc.Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue CommitmentsNASDAQ:ELABElevai Labs Inc
22/04/202409:00GlobeNewswire Inc.ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 MonthsNASDAQ:ELABElevai Labs Inc
29/03/202413:00GlobeNewswire Inc.Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial ResultsNASDAQ:ELABElevai Labs Inc
18/03/202409:51InvestorsHub NewsWireElevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical MarketNASDAQ:ELABElevai Labs Inc
24/01/202410:30GlobeNewswire Inc.ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark OfficeNASDAQ:ELABElevai Labs Inc
17/01/202411:07InvestorsHub NewsWireELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global ReachNASDAQ:ELABElevai Labs Inc
16/01/202412:05InvestorsHub NewsWireELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:ELABElevai Labs Inc
02/01/202411:15GlobeNewswire Inc.ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry ConferencesNASDAQ:ELABElevai Labs Inc
11/12/202311:15GlobeNewswire Inc.Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023NASDAQ:ELABElevai Labs Inc
07/12/202311:41GlobeNewswire Inc.ELEVAI Labs, Inc. Expands International Distribution into EuropeNASDAQ:ELABElevai Labs Inc
29/11/202311:00GlobeNewswire Inc.Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics ProductsNASDAQ:ELABElevai Labs Inc
24/11/202315:38PR Newswire (US)ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public OfferingNASDAQ:ELABElevai Labs Inc
24/11/202314:00GlobeNewswire Inc.Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB)NASDAQ:ELABElevai Labs Inc
23/06/200518:13Business WireEon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping ImmediatelyNASDAQ:ELABElevai Labs Inc
13/06/200518:41Business WireAppeals Court Affirms that Eon Labs' Itraconazole Does Not Infringe Janssen's PatentNASDAQ:ELABElevai Labs Inc
24/02/200416:34PR Newswire (US)Pacific Exchange to Trade Six New OptionsNASDAQ:ELABElevai Labs Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELAB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
TELB4
TELEBRAS PN
BOV
PRIO3
PETRORIO ON
BOV
TECN3
TECHNOS ON
BOV
GOLL4
GOL PN
BOV
BMGB4
BMG PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados